FDA Reopens BHA Review—Why One Preservative Is Becoming a Global Wake-Up Call for Food Additives

In a move that’s turning heads across the food industry, the U.S. FDA has launched a new post-market assessment of BHA (butylated hydroxyanisole)—a long-used antioxidant preservative found in many processed foods. 

The headline matters because it’s not just about one ingredient: it signals a broader regulatory pivot—rechecking “legacy” additives that entered the food supply decades ago under older scientific standards. 

What is BHA—and why is it suddenly back on the radar?

BHA has been used to slow oxidation in fats and oils, helping extend shelf life in products like snacks, cereals, and other packaged foods. 

The renewed attention stems from long-running health debates and the fact that BHA has been flagged in the U.S. National Toxicology Program context as “reasonably anticipated to be a human carcinogen,” based on animal data, which has fueled advocacy pressure for reassessment. 

The FDA’s current step is a Request for Information (RFI)—a way to gather updated evidence on today’s usage levels, exposure, and relevant science before determining next regulatory actions. 

Why this is bigger than BHA

Two structural shifts make this story eye-catching:

1) The U.S. is strengthening post-market oversight 

The FDA frames the BHA work as part of a strengthened program to systematically review chemicals already in the food supply, not only evaluate new additives at the front door. 

Reuters and AP reporting also connects this to a wider FDA push to reassess multiple chemicals, and to potential changes to the GRAS framework—the pathway that historically allowed some substances into the food supply without a traditional premarket approval process. 

2) Color additives are also in the spotlight  

In parallel, FDA’s Human Foods Program has highlighted work tied to color additive policy, including guidance on when certain fruit/vegetable juices qualify as color additives and a broader shift toward natural alternatives. 

The agency is also tracking industry pledges to remove petroleum-based certified colors from product portfolios—showing how regulation + consumer expectations are reshaping additive strategies at the brand level. 

Regulators worldwide are tightening the lens on additives 

While the U.S. BHA review is the headline grabber, it fits a broader global pattern: food additive policy is moving from “one-time approval” to “living re-evaluation.”

EU: Continuous re-evaluation + major sweetener decisions

The European Commission tracks the state of play of EFSA’s re-evaluation program for older additives, reflecting an ongoing pipeline of reassessments. 

In mid-February 2026, EFSA published a fresh conclusion on sucralose (E 955)—finding it safe for currently authorised uses, while also signaling how extensions or new conditions can be treated differently. 

China: New additive pathways under consultation

China’s CFSA has recently opened public comment on multiple items described as new food additives / related approvals (including categories such as enzymes, nutrition enhancers, and processing aids/expanded scopes), with a stated comment deadline. 

This highlights a different—but equally important—global dynamic: markets aren’t only restricting; they’re also modernizing approvals and expanding permitted uses through structured review. 

U.S. States: California pushes its own oversight agenda

California lawmakers introduced AB 2034, which would expand state-level authority around additive oversight and disclosures—an example of how sub-national policy can accelerate change even when federal timelines are slower. 

What food companies should watch next 

If you work in food, ingredients, or supply chains, the practical takeaways are clear: 

• Legacy additives are no longer “set and forget.” Expect more RFIs, re-evaluations, and data calls—especially for ingredients tied to controversy or high exposure in children’s products. 

• Data readiness becomes a competitive advantage. Companies that can quickly produce use-levels, technical function, exposure rationale, and updated safety dossiers will navigate these shifts more smoothly. 

• Reformulation risk is rising. If scrutiny expands from BHA to other preservatives, antioxidants, and color additives, supply chains may need validated replacements—with stability, sensory, and cost impacts. 

• Regulatory divergence will matter. A strategy that works in the EU (re-evaluation cadence, authorized uses) may not map 1:1 to U.S. federal/state dynamics or China’s consultation-driven approvals. 

The BHA review is a signal flare: regulators are moving toward continuous, evidence-updated governance of additives—especially those approved in an earlier scientific era. For industry, the next “big” additive headline may not be a brand-new molecule—it could be a decades-old ingredient that suddenly has to justify its place again.